2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. iGluR
  4. Lanicemine dihydrochloride

Lanicemine dihydrochloride  (Synonyms: AZD6765 dihydrochloride; ARL 15896AR)

Cat. No.: HY-108235A Purity: 99.94%
COA Handling Instructions

Molarity Calculator

Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (Ki of 0.56-2.1?μM for NMDA receptor; IC50s of 4-7?μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.

For research use only. We do not sell to patients.

Lanicemine dihydrochloride Chemical Structure

Lanicemine dihydrochloride Chemical Structure

CAS No. : 153322-06-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
5 mg USD 60 In-stock
10 mg USD 105 In-stock
25 mg USD 220 In-stock
50 mg USD 360 In-stock
100 mg USD 550 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Lanicemine dihydrochloride:

Lanicemine dihydrochloride Related Antibodies

Top Publications Citing Use of Products

View All iGluR Isoform Specific Products:

View All Isoforms
AMPA Receptor NMDA Receptor Kainate Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (Ki of 0.56-2.1?μM for NMDA receptor; IC50s of 4-7?μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects[1].

IC50 & Target

NMDA Receptor

 

In Vivo

Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[1]. Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats[1]
Dosage: 3, 10 or 30 mg/kg
Administration: Intraperitoneal
Result: Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity.
Clinical Trial
Molecular Weight

271.19

Formula

C13H16Cl2N2
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

N[C@H](C1=CC=CC=C1)CC2=CC=CC=N2.Cl.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 240 mg/mL (884.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 100 mg/mL (368.75 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.6875 mL 18.4373 mL 36.8745 mL
5 mM 0.7375 mL 3.6875 mL 7.3749 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 6 mg/mL (22.12 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 6 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (60.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 6 mg/mL (22.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 6 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (60.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (368.75 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.6875 mL 18.4373 mL 36.8745 mL 92.1863 mL
5 mM 0.7375 mL 3.6875 mL 7.3749 mL 18.4373 mL
10 mM 0.3687 mL 1.8437 mL 3.6875 mL 9.2186 mL
15 mM 0.2458 mL 1.2292 mL 2.4583 mL 6.1458 mL
20 mM 0.1844 mL 0.9219 mL 1.8437 mL 4.6093 mL
25 mM 0.1475 mL 0.7375 mL 1.4750 mL 3.6875 mL
30 mM 0.1229 mL 0.6146 mL 1.2292 mL 3.0729 mL
40 mM 0.0922 mL 0.4609 mL 0.9219 mL 2.3047 mL
50 mM 0.0737 mL 0.3687 mL 0.7375 mL 1.8437 mL
60 mM 0.0615 mL 0.3073 mL 0.6146 mL 1.5364 mL
80 mM 0.0461 mL 0.2305 mL 0.4609 mL 1.1523 mL
100 mM 0.0369 mL 0.1844 mL 0.3687 mL 0.9219 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lanicemine dihydrochloride Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lanicemine153322-06-6AZD6765 ARL 15896ARAZD 6765AZD-6765iGluRIonotropic glutamate receptorsAntidepressantefficacylanicemineNMDAchannelblockerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lanicemine dihydrochloride
Cat. No.:
HY-108235A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.